Faculty Profiles - TOYOOKA Shinichi

Papers - TOYOOKA Shinichi

Division display 761 - 780 of about 940 ／ All the affair displays >>

Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial Reviewed

Tetsuya Mitsudomi, Satoshi Morita, Yasushi Yatabe, Shunichi Negoro, Isamu Okamoto, Junji Tsurutani, Takashi Seto, Miyako Satouchi, Hirohito Tada, Tomonori Hirashima, Kazuhiro Asami, Nobuyuki Katakami, Minoru Takada, Hiroshige Yoshioka, Kazuhiko Shibata, Shinzoh Kudoh, Eiji Shimizu, Hiroshi Saito, Shinichi Toyooka, Kazuhiko Nakagawa, Masahiro Fukuoka

LANCET ONCOLOGY 11 ( 2 ) 121 - 128 2010.2

Language：English Publishing type：Research paper (scientific journal) Publisher：ELSEVIER SCIENCE INC

Background Patients with non-small-cell lung cancer harbouring mutations in the epidermal growth factor receptor (EGFR) gene respond well to the EGFR-specific tyrosine kinase inhibitor gefitinib. However, whether gefitinib is better than standard platinum doublet chemotherapy in patients selected by EGFR mutation is uncertain.
Methods We did an open label, phase 3 study (WJTOG3405) with recruitment between March 31, 2006, and June 22, 2009, at 36 centres in Japan. 177 chemotherapy-naive patients aged 75 years or younger and diagnosed with stage IIIB/IV non-small-cell lung cancer or postoperative recurrence harbouring EGFR mutations (either the exon 19 deletion or L858R point mutation) were randomly assigned, using a minimisation technique, to receive either gefitinib (250 mg/day orally; n=88) or cisplatin (80 mg/m(2), intravenously) plus docetaxel (60 mg/m(2), intravenously; n=89), administered every 21 days for three to six cycles. The primary endpoint was progression-free survival. Survival analysis was done with the modified intention-to-treat population. This study is registered with UMIN (University Hospital Medical Information Network in Japan), number 000000539.
Findings Five patients were excluded (two patients were found to have thyroid and colon cancer after randomisation, one patient had an exon 18 mutation, one patient had insufficient consent, and one patient showed acute allergic reaction to docetaxel). Thus, 172 patients (86 in each group) were included in the survival analyses. The gefitinib group had significantly longer progression-free survival compared with the cisplatin plus docetaxel goup, with a median progression-free survival compared with the cisplatin plus docetaxel goup, with a median progression-free survival time of 9.2 months (95% CI 8.0-13.9) versus 6.3 months (5.8-7.8; HR 0.489, 95% CI 0.336-0.710, log-rank p<0.0001). Myelosuppression, alopecia, and fatigue were more frequent in the cisplatin plus docetaxel group, but skin toxicity, liver dysfunction, and diarrhoea were more frequent in the gefitinib group. Two patients in the gefitinib group developed interstitial lung disease (incidence 2.3%), one of whom died.
Interpretation Patients with lung cancer who are selected by EGFR mutations have longer progression-free survival if they are treated with gefitinib than if they are treated with cisplatin plus docetaxel.

DOI： 10.1016/S1470-2045(09)70364-X

Web of Science

PubMed

researchmap

[Treatment strategy and outcomes of invading apical lung cancer]. Reviewed

Toyooka S, Sou J, Sugimoto R, Yamane M, Oto T, Yoshimasu T, Okamura Y, Sano Y, Date H, Miyoshi S

Kyobu geka. The Japanese journal of thoracic surgery 63 ( 1 ) 57 - 64 2010.1

The estrogen receptor influences microtubule-associated protein tau (MAPT) expression and the selective estrogen receptor inhibitor fulvestrant downregulates MAPT and increases the sensitivity to taxane in breast cancer cells Reviewed

Hirokuni Ikeda, Naruto Taira, Fumikata Hara, Takeo Fujita, Hiromasa Yamamoto, Junichi Soh, Shinichi Toyooka, Tomohiro Nogami, Tadahiko Shien, Hiroyoshi Doihara, Shinichiro Miyoshi

BREAST CANCER RESEARCH 12 ( 3 ) R43 2010

Language：English Publishing type：Research paper (scientific journal) Publisher：BIOMED CENTRAL LTD

Introduction: Microtubule-associated protein tau (MAPT) inhibits the function of taxanes and high expression of MAPT decreases the sensitivity to taxanes. The relationship between estrogen receptor (ER) and MAPT in breast cancer is unclear. In this study, we examined the correlation of MAPT expression with the sensitivity of human breast cancer cells to taxanes, and the relationship between ER and MAPT.
Methods: The correlation between MAPT expression and sensitivity to taxanes was investigated in 12 human breast cancer cell lines. Alterations in cellular sensitivity to taxanes were evaluated after knockdown of MAPT expression. ER expression was knocked down or stimulated in MAPT-and ER-positive cell lines to examine the relationship between ER and MAPT. The cells were also treated with hormone drugs (tamoxifen and fulvestrant) and taxanes.
Results: mRNA expression of MAPT did not correlate with sensitivity to taxanes. However, expression of MAPT protein isoforms of less than 70 kDa was correlated with a low sensitivity to taxanes. Downregulation of MAPT increased cellular sensitivity to taxanes. MAPT protein expression was increased by stimulation with 17-beta-estradiol or tamoxifen, but decreased by ER downregulation and by fulvestrant, an ER inhibitor. The combination of fulvestrant with taxanes had a synergistic effect, whereas tamoxifen and taxanes had an antagonistic effect.
Conclusions: Expression of MAPT protein isoforms of less than 70 kDa is correlated with a low sensitivity to taxanes in breast cancer cells. ER influences MAPT expression and fulvestrant increases the sensitivity to taxanes in MAPT-and ER-positive breast cancer cells.

DOI： 10.1186/bcr2598

Web of Science

PubMed

researchmap

Volume reduction surgery for pulmonary emphysema

Sugimoto, S., Oto, T., Soh, J., Yamane, M., Toyooka, S., Miyoshi, S.

Japanese Journal of Chest Diseases 69 ( SUPPL. ) 2010

CT fluoroscopy-guided biopsy of 1,000 pulmonary lesions performed with 20-gauge coaxial cutting needles: diagnostic yield and risk factors for diagnostic failure. Reviewed International journal

Hiraki T, Mimura H, Gobara H, Iguchi T, Fujiwara H, Sakurai J, Matsui Y, Inoue D, Toyooka S, Sano Y, Kanazawa S

Chest 136 ( 6 ) 1612 - 1617 2009.12

Language：English Publishing type：Research paper (scientific journal)

BACKGROUND: Although conventional CT scan-guided needle biopsy is an established diagnostic method for pulmonary lesions, few large studies have been conducted on the diagnostic outcomes of CT fluoroscopy-guided lung biopsy. We have conducted a retrospective analysis to evaluate the diagnostic outcomes of 1,000 CT fluoroscopy-guided lung biopsies performed with 20-gauge coaxial cutting needles. METHODS: We determined the diagnostic yield of CT fluoroscopy-guided lung biopsies performed with 20-gauge coaxial cutting needles for 1,000 lesions in 901 patients. Independent risk factors for diagnostic failure (ie, nondiagnostic, false-positive, and false-negative results) were determined with multivariate logistic regression analysis. RESULTS: The biopsy results were nondiagnostic in 0.6% of the lesions (6 of 1,000 lesions). The sensitivity and specificity for the diagnosis of malignancy was 94.2% (741 of 787 lesions) and 99.1% (211 of 213 lesions), respectively; diagnostic accuracy was 95.2% (952 of 1,000 lesions). For lesions measuring <or= 1.0 cm, the diagnostic accuracy was 92.7% (140 of 151 lesions). The significant independent risk factors for diagnostic failure were as follows: the acquisition of two or fewer specimens (odds ratio [OR], 2.43; p = 0.007), lesions in the lower lobe (OR, 2.50; p = 0.003), malignant lesions (OR, 7.16; p = 0.007), and lesions measuring <or= 1.0 cm (OR, 3.85; p = 0.016) and >or= 3.1 cm (OR, 4.32; p = 0.007). CONCLUSIONS: CT fluoroscopy-guided lung biopsy performed with 20-gauge coaxial cutting needles resulted in a high diagnostic yield, even in the case of small lesions. Factors such as the acquisition of two or fewer specimens, lesions in the lower lobe, malignant lesions, and lesions measuring <or= 1.0 cm or >or= 3.1 cm significantly increased the rate of diagnostic failure.

DOI： 10.1378/chest.09-0370

PubMed

researchmap

Percutaneous computed tomography-guided lung biopsy and pleural dissemination: an assessment by intraoperative pleural lavage cytology. Reviewed

Sano Y, Date H, Toyooka S, Oto T, Yamane M, Hiraki T, Gobara H, Mimura H, Kanazawa S

Cancer 115 ( 23 ) 5526 - 5533 2009.12

Extracorporeal membrane oxygenation bridging to living-donor lobar lung transplantation. Reviewed

Miyoshi K, Oto T, Okazaki M, Yamane M, Toyooka S, Goto K, Sano Y, Sano S, Miyoshi S

The Annals of thoracic surgery 88 ( 5 ) e56 - 7 2009.11

Usefulness of cumulative smoking dose for identifying the EGFR mutation and patients with non-small-cell lung cancer for gefitinib treatment. Reviewed

Jida M, Toyooka S, Mitsudomi T, Takano T, Matsuo K, Hotta K, Tsukuda K, Kubo T, Yamamoto H, Yamane M, Oto T, Sano Y, Kiura K, Yatabe Y, Ohe Y, Date H, Miyoshi S

Cancer science 100 ( 10 ) 1931 - 1934 2009.10

肺尖部肺癌に対する外科的戦略肺尖部胸壁浸潤肺癌に対する治療外科治療を中心として

豊岡伸一, 宗淳一, 山根正修, 大藤剛宏, 吉増達也, 岡村吉隆, 佐野由文, 三好新一郎

日本臨床外科学会雑誌 70 ( 増刊 ) 337 - 337 2009.10

Oncogene mutations, copy number gains and mutant allele specific imbalance (MASI) frequently occur together in tumor cells. Reviewed

Soh J, Okumura N, Lockwood WW, Yamamoto H, Shigematsu H, Zhang W, Chari R, Shames DS, Tang X, MacAulay C, Varella-Garcia M, Vooder T, Wistuba II, Lam S, Brekken R, Toyooka S, Minna JD, Lam WL, Gazdar AF

PloS one 4 ( 10 ) e7464 2009.10

原発性肺癌に対する内照射後に気管支狭窄を繰り返した1例

渡邉元嗣, 大藤剛宏, 岡崎幹生, 豊岡伸一, 佐野由文, 三好新一郎

日本臨床外科学会雑誌 70 ( 増刊 ) 812 - 812 2009.10

ブタ胸管のシーリングによって証明された、縦隔リンパ節郭清におけるハーモニックの有用性

岡崎幹生, 豊岡伸一, 大谷真二, 山根正修, 大藤剛宏, 佐野由文, 三好新一郎

肺癌 49 ( 5 ) 671 - 671 2009.10

肺腺癌におけるKRAS遺伝子変化の生物学的活性および予後に対する効果の検討

宗淳一, 豊岡伸一, 山本寛斉, 重松久之, 山根正修, 大藤剛宏, 佐野由文, 三好新一郎

肺癌 49 ( 5 ) 624 - 624 2009.10

当院における縦隔原発非セミノーマ胚細胞腫瘍に対する集学的治療

二宮崇, 木浦勝行, 瀧川奈義夫, 佐野由文, 大藤剛宏, 豊岡伸一, 山根正修, 堀田勝幸, 田端雅弘, 谷本光音, 三好新一郎, 伊達洋至

肺癌 49 ( 5 ) 645 - 645 2009.10

術前induction治療後の手術手技術前放射線同時併用化学療法後の肺切除手術手技

佐野由文, 豊岡伸一, 大藤剛宏, 山根正修, 木浦勝行, 田端雅弘, 瀧川奈義夫, 堀田勝幸, 武本充広, 三好新一郎

肺癌 49 ( 5 ) 574 - 574 2009.10

局所進行非小細胞肺癌に対する集学的治療の現状と展望縦隔リンパ節転移を伴う非小細胞肺癌に対する術前放射線同時併用化学療法の治療成績

豊岡伸一, 木浦勝行, 武本充広, 山根正修, 大藤剛宏, 枝園和彦, 堀田勝幸, 頼冠名, 瀧川奈義夫, 田端雅弘, 佐野由文, 伊達洋至, 三好新一郎

肺癌 49 ( 5 ) 578 - 578 2009.10

生体肺移植のドナー手術における安全性の検討

佐野由文, 大藤剛宏, 豊岡伸一, 山根正修, 岡崎幹生, 石原恵, 三好新一郎

移植 44 ( 総会臨時 ) 315 - 315 2009.9

肺高血圧症crisisに対するVA-ECMOをbridgeとした両側生体肺移植

三好健太郎, 大藤剛宏, 岡崎幹生, 山根正修, 豊岡伸一, 佐野由文, 三好新一郎

移植 44 ( 総会臨時 ) 316 - 316 2009.9

小児期から青年期における胸部悪性腫瘍の臨床的特徴と外科的治療

佐野由文, 豊岡伸一, 大藤剛宏, 山根正修, 木浦勝行, 田端雅弘, 瀧川奈義夫, 堀田勝幸, 三好新一郎

日本癌治療学会誌 44 ( 2 ) 535 - 535 2009.9

Clinical outcomes of short hook wire and suture marking system in thoracoscopic resection for pulmonary nodules Reviewed

Kentaroh Miyoshi, Shinichi Toyooka, Hideo Gobara, Takahiro Oto, Hidefumi Mimura, Yoshifumi Sano, Susumu Kanazawa, Hiroshi Date

EUROPEAN JOURNAL OF CARDIO-THORACIC SURGERY 36 ( 2 ) 378 - 382 2009.8

Language：English Publishing type：Research paper (scientific journal) Publisher：ELSEVIER SCIENCE BV

Objective: The short hook wire and suture marking system is a device for localization of small pulmonary nodules in thoracoscopic resection. We and other authors have shown the feasibility of the marking procedure. In this study, we reviewed our recent experience to examine the problems for resecting procedure using the device and determine if the system negatively impacts the survival rates for lung cancers. Methods: Between November 1996 and March 2007, a total of 125 pulmonary nodular lesions in 108 patients were intended for thoracoscopic resection after localization with computed tomography-guided short hook wire and suture placement. We reviewed the major problems during surgery among all cases and prognosis in 64 patients with primary lung cancer. Results: One hundred and seventeen lesions (93.6%) were successfully resected by intitial resection with no major complication. However, we experienced missing events, the major problem during surgery, which was defined as temporarily missing lesions or hook wires. Eight missing events (6.4%) consisting of five unresected lesions and three remaining hook wires occurred after initial wedge resection. All the missing lesions and one remaining hook wire were recovered by additional resection. No specific factors of lesions, including location, diameter, distance from the pleural surface, and opacification were related to incidence of the 'missing event'. Five-year survival of patients with stage IA lung cancer was 90.0% with no local recurrence. Conclusions: Our localization method assured a consistent quality of resection regardless of the lesion characteristics and a reasonable prognosis for patients with primary lung cancer. The short hook wire and suture system provides acceptable utility in thoracoscopic surgery. (C) 2009 European Association for Cardio-Thoracic Surgery. Published by Elsevier B.V. All rights reserved.

DOI： 10.1016/j.ejcts.2009.03.039

Web of Science

researchmap

　 PREV - NEXT 　

< TOYOOKA Shinichi >

Papers - TOYOOKA Shinichi